Clinical Study

Dipeptidyl Peptidase 4 Inhibition May Facilitate Healing of Chronic Foot Ulcers in Patients with Type 2 Diabetes

Table 1

Baseline characteristics of study patients.

Control groupVildagliptin groupP

N 5353
Mean age (years) 63 ± 1564 ± 17NS
Sex (M/F) 34/1935/18NS
BMI 29 ± 2.830 ± 2.1NS
Diabetes duration (years)16 ± 617 ± 5NS
Waist-to-hip ratio 0.91 ± 0.060.92 ± 0.09NS
Systolic blood pressure (mmHg) 131 ± 18129 ± 16NS
Diastolic blood pressure (mmHg) 79 ± 880 ± 7NS
Heart rate (bpm) 83 ± 2684 ± 24NS
Laboratory results
 Glycated hemoglobin (%)8.0 ± 1.28.1 ± 1.3NS
 Plasma glucose (mg/dL)168 ± 33170 ± 36NS
 Creatinine (mg/dL)1.1 ± 0.61.0 ± 0.8NS
 Colesterol (mg/dL)230 ± 49234 ± 51NS
 Triglycerides (mg/dL)166 ± 63171 ± 69NS
 HDL (mg/dL)36 ± 1235 ± 11NS
 LDL (mg/dL)162 ± 23165 ± 30NS
Risk factors
 Hypertension (%)32 (61)33 (62)NS
 Hyperlipidemia (%)25 (47)26 (48)NS
 CAD (%)22 (41)21 (39)NS
 Stroke (%)5 (10)4 (7)NS
 Previous smokers (%)19 (36)20 (38)NS
 Active smokers (%)5 (10)6 (12) NS
Therapy
 Insulin (%)14 (26)14 (26)NS
 Metformin (%)26 (50)28 (52)NS
 Sulfonylurea (%)11 (21)10 (19)NS
 Statin (%)42 (80)43 (81)NS
 Aspirin (%)34 (64)36 (67)NS
 Clopidogrel (%)6 (11)7 (13)NS
 Warfarin (%)4 (7 )5 (10)NS
 ACE-inhibitor or ARB (%) 31 (60)30 (58)NS
β-blocker (%)14 (26)15 (29)NS
 Diuretics (%)33 (62) 36 (67)NS
Ankle-brachial index (mmHg)1.0 ± 0.11.0 ± 0.2NS
Transcutaneous oxygen tension (mmHg)44.9 ± 12.144.2 ± 11.8NS
Ulcer duration before treatment (days)122 ± 22126 ± 26NS
Plantar foot ulcers (%)32 (61)33 (62)NS
Dorsal foot ulcers (%)11 (21)10 (19)NS
Lateral foot ulcers (%)10 (19)10 (19)NS
Baseline wound area (cm2) 4.1 ± 1.24.3 ± 1.5NS
Off-loading methods
 Accommodative dressing (%)30 (60)30 (60)NS
 Healing shoe (%)3 (6)5 (9)NS
 Walking splint (%)1 (2)1 (2)NS

Data are means ± SD or (%).